-+ 0.00%
-+ 0.00%
-+ 0.00%

Repligen Appoints Martin D. Madaus Board Chair, Effective March 13, Succeeding Tony Hunt

Benzinga·01/06/2026 12:31:26
Listen to the news

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.